Finding the Best Treatment Combinations for Advanced Gastric Cancer
Recruiting · Phase 2 · Gastric Cancer · 9 states
About this trial
This study looks at the safety and effectiveness of a treatment called trastuzumab deruxtecan (T-DXd) for patients with advanced gastric cancer that express a protein called HER2. The goal is to see how well T-DXd works alone or with other treatments like chemotherapy and immunotherapy. Researchers hope to find a combination that helps control the cancer better than previous options.
The trial's ID number is NCT04379596. This is a Phase 2 study, which means it looks at how well the treatment works and how safe it is. It is regulated by the FDA and aims to include about 450 participants.
Who can join
Adults aged 18 and older can join this study. Both men and women are welcome. Participants should have advanced gastric cancer that has not been treated before or should have disease progression after previous treatments. The trial team will check to confirm eligibility.
Age group
Adult, Older adult
The study team makes the final call on eligibility.
What happens in the study
Participants will be assigned to different groups by chance. Each group will receive a different combination of treatments. Some will get T-DXd with chemotherapy or immunotherapy, while others may receive T-DXd alone. The study will compare these groups to see which combinations work best.
Where
This trial is enrolling at 10 locations. Recruiting sites are listed first.